Combinatorial chemistry identifies additional compounds that selectively inhibit DLK-dependent retrograde signaling while minimally affecting other axonal roles of DLK
Open Access
- 27 January 2026
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Dual leucine-zipper kinase (DLK) is implicated in at least two distinct processes that drive neurodegeneration: retrograde (axon-to-soma) signaling to activate pro-degenerative transcription programs, and axon-intrinsic action to drive Wallerian and Wallerian-like axon degeneration. Inhibiting DLK-dependent signaling is thus an attractive neuroprotective strategy, but compounds that inhibit all cellular pools of DLK cause unintended side effects. We recently successfully deployed a complementary approach to identify compounds that selectively block DLK retrograde (axon-to-soma) signaling and subsequent neurodegeneration by inhibiting acute, axonal palmitoylation of DLK. Here, we explored chemical space for one of our two most effective compounds and identified multiple analogs that are equally neuroprotective in a model of transcription-dependent neurodegeneration that requires DLK-dependent retrograde signaling. In contrast, our original hits and these additional analogs had minimal effect in two models of DLK-dependent, but transcription-independent, distal axon degeneration. Moreover, our original hits did not phenocopy the stabilization of axon survival factor proteins that is a well-described effect of conventional DLK kinase domain inhibitors. These findings reveal additional potential neuroprotective compounds and further support the notion that the pool of DLK that conveys axonal retrograde signals can be selectively targeted therapeutically.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01 NS094402)
- National Eye Institute (EY029386)
- Shriners Hospitals for Children (#85190 PHI)
This publication has 44 references indexed in Scilit:
- The Stathmin-2 membrane-targeting domain is required for axon protection and regulated degradation by DLK signalingJournal of Biological Chemistry, 2023
- A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALSAnnals of Clinical and Translational Neurology, 2022
- Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to DegenerateCell Reports, 2021
- Coupled Control of Distal Axon Integrity and Somal Responses to Axonal Damage by the Palmitoyl Acyltransferase ZDHHC17Cell Reports, 2020
- DLK Activation Synergizes with Mitochondrial Dysfunction to Downregulate Axon Survival Factors and Promote SARM1-Dependent Axon DegenerationMolecular Neurobiology, 2019
- Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluationEuropean Journal of Medicinal Chemistry, 2018
- Axon Degeneration Gated by Retrograde Activation of Somatic Pro-apoptotic SignalingCell, 2016
- Pathological Axonal Death through a MAPK Cascade that Triggers a Local Energy DeficitCell, 2015
- Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrierInternational Journal of Pharmaceutics, 2005
- Syntheses of 5‐alkylthio‐1,3‐diaryl‐1,2,4‐triazolesJournal of Heterocyclic Chemistry, 2004